a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the mechanism of action of petosemtamab, which is designed to combat cancer by blocking EGFR ligands ...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Phanes Therapeutics begins patient dosing in clinical study of mavrostobart in combination with chemotherapy: San Diego Wednesday, May 28, 2025, 18:00 Hrs [IST] Phanes Therapeutic ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the ...

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...